Covid Drug: New oral antiviral drug likely to get Centre’s approval for treating Covid, Health News, ET HealthWorld

Pune: The Union health ministry is likely to include an oral antiviral drug, nirmatrelvir-ritonavir combination, in the country’s upcoming Covid treatment protocol for patients with mild to moderate disease, who are at high risk of developing severe illness. The combination drug, popularly known by the brand name paxlovid, is currently in high demand in China and a few other nations battling the Covid surge. India’s upcoming Covid treatment protocol is expected to be released within a week. “The combination two-tablet oral drug therapy is likely to be recommended in India…

Read More

Antiviral drug ‘Clevira’ repurposed for treating mild to moderate Covid-19 patients – ET HealthWorld

Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate Covid-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday. The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days. The drug has also proved to be safe on liver and kidney parameters, it said. “Clevira, an antiviral formulation, has received regulatory approval as a supportive treatment for mild to moderate Covid-19 cases,” the Chennai-based pharmaceutical company said. “Clevira was developed…

Read More

Russia offers oxygen and Remdesivir to India, imports likely to begin in the next 15 days – ET HealthWorld

Russia has offered to supply medical oxygen and Remdesivir to India and imports are likely to begin in the next 15 days. Indian hospitals have been reporting dwindling supplies of oxygen due to the surge in Covid-19 cases in the country. Stocks of antiviral drug Remdesivir used to treat the disease, have also been running out. Moscow has said it can supply 300,000-400,000 Remdesivir injections per week, which would be increased. Talks are on to begin oxygen supplies by ship soon, officials said. “Russia has offered to supply 3-4 lakh…

Read More